BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

This study has been completed.
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: June 5, 2003
Last updated: May 29, 2013
Last verified: July 2004

RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.

Condition Intervention Phase
Drug: forodesine hydrochloride
Phase 1
Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL)

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: February 2003
Study Completion Date: January 2008
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated dose of BCX-1777 in patients with refractory cutaneous T-cell lymphoma.
  • Determine the efficacy of this drug in these patients.
  • Determine the toxicity profile of this drug in these patients.
  • Correlate plasma concentration of deoxyguanosine with clinical response and toxicity in patients treated with this drug.
  • Determine the provisional optimal biological dose of this drug in these patients.

OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study.

  • Phase I: Patients receive BCX-1777 IV over 30 minutes every 12 hours on days 1-5 (a total of 9 doses). Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose-limiting toxicity.

  • Phase II: Patients receive treatment as in phase I at the MTD of BCX-1777. Patients (including those who respond to treatment) are followed at 14 and 30 days, monthly for 6 months, every 2 months for 6 months, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 3-64 patients (3-24 for phase I and 40 for phase II) will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed cutaneous T-cell lymphoma (CTCL)

    • Any stage except IA patch only
  • Previously treated according to 1 of the following:

    • Stage IA plaque, IB, or IIA:

      • At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light [PUVA] and systemic corticosteroids)
    • Stage IIB, III, or IV:

      • At least 1 prior systemic regimen (systemic corticosteroids and PUVA do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered one regimen
  • Measurable disease



  • 18 and over

Performance status

  • ECOG 0-3

Life expectancy

  • At least 3 months


  • Granulocyte count at least 2,000/mm^3
  • Platelet count at least 75,000/mm^3
  • Hemoglobin at least 10.0 g/dL


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome)
  • ALT no greater than 2 times ULN
  • Alkaline phosphatase no greater than 2 times ULN
  • No hepatitis B or C


  • Creatinine clearance at least 45 mL/min


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • Human T-cell leukemia virus type 1 (HTLV-1) negative
  • No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No other illness that would limit study participation
  • No active serious infection not controlled by antibiotics


Biologic therapy

  • No concurrent anticancer antibody therapy
  • No concurrent anticancer immunotherapy
  • No concurrent anticancer gene therapy
  • No concurrent anticancer vaccine therapy
  • No concurrent anticancer angiogenesis inhibitors
  • No concurrent sargramostim (GM-CSF)
  • No concurrent filgrastim (G-CSF) during course 1 of therapy


  • More than 21 days since prior chemotherapy unless fully recovered
  • No concurrent anticancer chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • More than 2 weeks since prior topical corticosteroids
  • No concurrent anticancer hormonal therapy


  • More than 2 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • Not specified


  • More than 2 weeks since prior antineoplastic therapy
  • More than 21 days since prior investigational agents unless fully recovered
  • No concurrent citrate-blood products within 30 minutes before or after study treatment
  • No concurrent anticancer matrix metalloprotease inhibitors
  • No other concurrent anti-CTCL therapy
  • No concurrent use of tanning beds
  • No other concurrent investigational agents
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00061880

United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294-3300
United States, North Carolina
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
BioCryst Pharmaceuticals
Study Chair: Alex Shalaurov, MD, PhD Inveresk Research Group, Incorporated
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00061880     History of Changes
Other Study ID Numbers: BIOCRYST-1777BC-103, CDR0000301763
Study First Received: June 5, 2003
Last Updated: May 29, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent cutaneous T-cell non-Hodgkin lymphoma
stage I cutaneous T-cell non-Hodgkin lymphoma
stage II cutaneous T-cell non-Hodgkin lymphoma
stage III cutaneous T-cell non-Hodgkin lymphoma
stage IV cutaneous T-cell non-Hodgkin lymphoma
recurrent mycosis fungoides/Sezary syndrome
stage I mycosis fungoides/Sezary syndrome
stage II mycosis fungoides/Sezary syndrome
stage III mycosis fungoides/Sezary syndrome
stage IV mycosis fungoides/Sezary syndrome

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on April 17, 2014